

AR12 (clean)

1. Collagen hydrolysate for use in prevention and/or treatment of post-intensive care syndrome (PICS) after intensive care unit stay, wherein the use is in ameliorating a physical symptom, a mental symptom and a cognitive symptom in PICS, and wherein the collagen hydrolysate is administered after intensive care unit stay, and wherein the collagen hydrolysate is administered as a food supplement formulation.
2. Collagen hydrolysate for use according to claim 1, wherein the collagen hydrolysate is administered at 10 - 100 g total dose per day, based on the dry weight amount of the collagen hydrolysate.
3. Collagen hydrolysate for use according to any one of the previous claims, wherein the dosage regimen for collagen hydrolysate comprises administering collagen hydrolysate for at least 3 consecutive weeks after intensive care unit stay.
4. Collagen hydrolysate for use according to any one of the previous claims, wherein the dosage regimen for collagen hydrolysate comprises administration of collagen hydrolysate starting within 3 weeks after intensive care unit stay.
5. Collagen hydrolysate for use according to any one of the previous claims, wherein the dosage regimen for collagen hydrolysate comprises administering collagen hydrolysate at least once every day or at least once every other day.
6. Collagen hydrolysate for use according to any one of the previous claims, wherein the collagen hydrolysate has an average molecular weight of 1000 - 9000 Da.
7. Collagen hydrolysate for use according to any one of the previous claims, wherein the collagen hydrolysate has an average molecular weight of less than 5000 Da.
8. Collagen hydrolysate for use according to claim 7, wherein the collagen hydrolysate has an average molecular weight of 1400 - 2200 Da, preferably 1600 - 2000 Da.